The third study failed to define any significant association between Beclin-1 alone and clinical outcome in ESCC, but demonstrated that negative co-expression of Beclin-1 and LC3 correlated with poor survival as compared to positive co-expression of the two proteins [35]. The gene discussed is MAP1LC3A; the disease is esophageal squamous cell carcinoma.